[go: up one dir, main page]

UY32598A - Sal de abt-263 y formas en estado sólido de la misma - Google Patents

Sal de abt-263 y formas en estado sólido de la misma

Info

Publication number
UY32598A
UY32598A UY0001032598A UY32598A UY32598A UY 32598 A UY32598 A UY 32598A UY 0001032598 A UY0001032598 A UY 0001032598A UY 32598 A UY32598 A UY 32598A UY 32598 A UY32598 A UY 32598A
Authority
UY
Uruguay
Prior art keywords
abt
forms
salt
same
solid state
Prior art date
Application number
UY0001032598A
Other languages
English (en)
Inventor
Lou Xiaochun
Zhou Deliang
Catron Nathaniel
Borchardt Thomas
Brackemeyer Paul
Henry Rodger
Ravn Matthew
Zhang Geoff
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY32598A publication Critical patent/UY32598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La ABT-263 bis-HCI y sus formas polimórficas cristalinas son ingredientes farmacéuticos activos apropiados para composiciones farmacéuticas útiles en el tratamiento de una enfermedad caracterizada por la sobreexpresión de una o más proteínas antiapoptóticas de la familia Bcl-2, por ejemplo, el cáncer.
UY0001032598A 2009-04-30 2010-04-30 Sal de abt-263 y formas en estado sólido de la misma UY32598A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17427409P 2009-04-30 2009-04-30

Publications (1)

Publication Number Publication Date
UY32598A true UY32598A (es) 2010-12-31

Family

ID=42288743

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032598A UY32598A (es) 2009-04-30 2010-04-30 Sal de abt-263 y formas en estado sólido de la misma

Country Status (17)

Country Link
US (1) US8362013B2 (es)
EP (1) EP2424849A1 (es)
JP (1) JP2012525433A (es)
KR (1) KR20120005538A (es)
CN (1) CN102414186A (es)
AR (1) AR076509A1 (es)
AU (1) AU2010242923A1 (es)
BR (1) BRPI1014369A2 (es)
CA (1) CA2758740A1 (es)
IL (1) IL215472A0 (es)
MX (1) MX2011011511A (es)
RU (1) RU2011148521A (es)
SG (1) SG175146A1 (es)
TW (1) TW201041882A (es)
UY (1) UY32598A (es)
WO (1) WO2010127190A1 (es)
ZA (1) ZA201107592B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP2013505249A (ja) * 2009-09-20 2013-02-14 アボット・ラボラトリーズ Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物
BR112012014499A2 (pt) * 2009-12-22 2016-08-16 Abbott Lab cápsula de abt-263
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102584744B (zh) * 2011-01-06 2015-07-01 上海药明康德新药开发有限公司 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CA2939121C (en) * 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
US20170202782A1 (en) * 2014-04-06 2017-07-20 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
EP3169366A1 (en) 2014-07-14 2017-05-24 Gilead Sciences, Inc. Combinations for treating cancers
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
BR112022008683A2 (pt) 2019-11-05 2022-07-19 Abbvie Inc Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax
US20230165806A1 (en) * 2021-11-19 2023-06-01 Board Of Regents, The University Of Texas System Topical Therapy of Skin Fibrosis and Melanoma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630663A (en) * 1899-05-01 1899-08-08 Wallace George Cook Combined hay and stock rack.
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
KR101533268B1 (ko) * 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
CN101939008A (zh) 2007-12-06 2011-01-05 雅培制药有限公司 用于治疗癌症的abt-263经口组合物
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2012530704A (ja) * 2009-06-18 2012-12-06 アボット・ラボラトリーズ 安定なナノ粒子状薬物懸濁液
JP2013505249A (ja) * 2009-09-20 2013-02-14 アボット・ラボラトリーズ Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
EP2424849A1 (en) 2012-03-07
IL215472A0 (en) 2011-12-29
WO2010127190A1 (en) 2010-11-04
TW201041882A (en) 2010-12-01
ZA201107592B (en) 2012-06-27
MX2011011511A (es) 2011-11-18
CA2758740A1 (en) 2010-11-04
SG175146A1 (en) 2011-11-28
JP2012525433A (ja) 2012-10-22
CN102414186A (zh) 2012-04-11
KR20120005538A (ko) 2012-01-16
BRPI1014369A2 (pt) 2016-04-05
US20100305125A1 (en) 2010-12-02
AR076509A1 (es) 2011-06-15
US8362013B2 (en) 2013-01-29
RU2011148521A (ru) 2013-06-10
AU2010242923A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
UY32598A (es) Sal de abt-263 y formas en estado sólido de la misma
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
BRPI0810552A2 (pt) Composição de substância ativa, processos para preparar uma composição de substância ativa, e para preparar sementes contenda substância ativa, uso da composição de substância ativa, sementes, e, composição aquosa.
CL2011001313A1 (es) Compuestos derivados de n-(fenil)-sulfonilamina, inhibidores de bcl2 o bcl-xl; composicion farmaceutica; y su uso en el tratamiento de cancer de vejiga, cerebro, mamas, medula osea, cervical, colorrectal, esofago, cancer hepatocelular, leucemia linfoblastica, linfoma folicular, mieloma.
CL2013000850A1 (es) Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros.
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
BR112013028666A2 (pt) compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CR20110388A (es) Compuestos heterocíclicos y métodos de uso
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
CL2007003192A1 (es) Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
AR079160A1 (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
IL211120A (en) Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
CL2011000713A1 (es) Composicion farmaceutica antiparasitaria oral subtoxica de imidacloprid para el control sistemico de parasitos hematofagos.
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127